Publication Name	World Journal of Clinical Cases
Manuscript ID	72745
Country	China

Category	Hematology
Manuscript Type	Case Report
Article Title	Chidamide and sintilimab combination in diffuse large B-cell lymphoma progressing after chimeric antigen receptor T therapy
Manuscript Source	Unsolicited Manuscript
All Author List	Yuan-Yuan Hao, Pan-Pan Chen, Xiang-Gui Yuan, Ai-Qi Zhao, Yun Liang, Hui Liu and Wen-Bin Qian
Funding Agency and Grant Number
Corresponding Author	Wen-Bin Qian, MD, PhD, Doctor, Professor, Department of Hematology, The Second Affiliated Hospital of Zhejiang University School of Medicine, No. 88 Jiefang Road, Hangzhou 310009, Zhejiang Province, China. qianwb@zju.edu.cn
Key Words	Chimeric antigen receptor T cell therapy; Diffuse large B-cell lymphoma; Immunotherapy; PD-1 inhibitor; Histone deacetylase inhibitor; Case report
Core Tip	We used histone deacetylase inhibitor chidamide combined with PD-1 blockade sintilimab for 7 patients with diffuse large B-cell lymphoma progressing after CART therapy. There are 2 complete response rates (CRs) and 2 PRs during this novel therapy, with an overall response rates of 57.1%, and one patient had a durable CR that lasted at least 20 mo.
Citation	Hao YY, Chen PP, Yuan XG, Zhao A, Liang Y, Liu H, Qian W. Histone deacetylase inhibitor chidamide and PD-1 blockade combination in diffuse large B-cell lymphoma progressing after CD19-targeting chimeric antigen receptor T cells therapy. World J Clin Cases 2022; 10(19): 6555-6562

Received	2021-10-31 03:52
Peer-Review Started	2021-10-31 03:53
To Make the First Decision
Return for Revision	2022-03-07 02:03
Revised	2022-04-10 06:51
Second Decision	2022-05-11 03:02
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2022-05-12 19:44
Articles in Press	2022-05-12 19:44
Publication Fee Transferred
Edit the Manuscript by Language Editor	2022-05-03 00:12
Typeset the Manuscript	2022-06-16 01:01

ISSN	2307-8960 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Copyright	©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com